Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
OLMA
OLMA | US
21.55
USD-1.01
-4.48%
OLMA | US
About OLMA
Sector
Healthcare
Industry
Biotechnology
Earnings date
30/06/2024
As of date
06/03/2026
Close
21.55
Open
21.80
High
22.44
Low
21.20
Olema Pharmaceuticals Inc. a clinical-stage biopharmaceutical company focuses on the discovery development and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250 an estrogen receptor (ER) antagonist and a selective ER degrader which is in Phase 1/2 clinical trial for the treatment of recurrent locally advanced or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib ribociclib and alpelisib in Phase 1b/2 clinical trial for the treatment of recurrent locally advanced or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer. The company was formerly known as CombiThera Inc. and changed its name to Olema Pharmaceuticals Inc. in March 2009. Olema Pharmaceuticals Inc. was incorporated in 2006 and is headquartered in San Francisco California.
View LessOLMA | US
Risk
52.4
Sharpe
2.51
Luna's Score
46/100
Recommendation
Hold
Luna says (OLMA | US)
What's Working
Low Debt to Equity (< 0.25)
Low Debt to Asset (< 0.2)
Strong Sharpe Ratio (> 1.2)
What's not Working
Negative Momentum (Declining Price)
Price Below SMA10D
High 6-Month Volatility (>65%)
Smallcap (300M - 2B USD)
High Market Beta (> 0.8)
High Short percentage (> 15%)
Volatility Signals
Bearish: Increased Volatility (6-month > 1-month volatility)
Risk Meter
10 days
50.0%1 month
52.4%3 months
70.3%6 months
212.0%Returns
Fundamental Ratios
PE
-
Fwd. PE
-
Price to book
3.10
Debt to equity
0.01
Debt to assets
0.01
Ent. to EBITDA
-3.33
Ent. to rev.
-
PEG
-
Other Fundamentals
EBITDA
-122.27M
MarketCap
1.23B
MarketCap(USD)
1.23B
Div. yield
-
Op. margin
-
Erngs. growth
-
Rev. growth
-
Ret. on equity
-56.40
Short ratio
15.23
Short perc.
25.81
Market Sentiment (SMA and Price signals)
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
SMAs: Stock Price Trends
Range10D
4.11
Range1M
5.93
Range3M
15.06
Volumes: Market Activity
Rel. volume
0.87
Price X volume
23.86M
Peers
Diversifiers
Industry Comparison
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | -3.33 | 0.53 | Cheaper |
| Ent. to Revenue | - | 3,967.00 | - |
| PE Ratio | - | 41.03 | - |
| Price to Book | 3.10 | 15.55 | Cheaper |
| Dividend Yield | - | 2.20 | - |
| Std. Deviation (3M) | 70.34 | 72.80 | Par |
| Debt to Equity | 0.01 | -1.23 | Expensive |
| Debt to Assets | 0.01 | 0.25 | Cheaper |
| Market Cap | 1.23B | 3.66B | Emerging |
